At Jazz, we believe that innovation should be measured by the impact it can have on people’s lives, especially those facing some of the most challenging diagnoses, often with few or no treatment options.
That belief guides where we focus our innovation in oncology—on some of the most difficult-to-treat cancers with the highest unmet needs. Our focus to advance cancer treatments continues to expand. Today, our oncology portfolio and pipeline programs span biliary tract cancer (BTC), gastroesophageal adenocarcinoma (GEA), extensive-stage small cell lung cancer (ES-SCLC), metastatic breast cancer (mBC), colorectal cancer (CRC) and other solid tumors, as well as hematologic malignancies such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and veno-occlusive disease (VOD). More recently, we have expanded into a rare central nervous system tumor known as H3 K27M-mutant diffuse midline glioma (DMG), a devastating disease primarily affecting children and young adults.
One of the most meaningful examples of our purpose-driven strategy in action is our latest clinical research in ES-SCLC. Small cell lung cancer (SCLC) accounts for just 10–15% of all lung cancers,i yet its impact is anything but small. It is one of the most aggressive and deadly solid tumors, often diagnosed at an advanced stage and marked by a rapid, unforgiving disease course. Median survival following relapse is measured in months, and for most, standard therapies offer only temporary control.
Not only does SCLC pose significant challenges to people living with this difficult-to-treat cancer, but patients and caregivers are also often faced with compressed timelines for education, planning and support. The speed at which SCLC develops in the body also challenges healthcare systems. Clinicians must make rapid treatment decisions, often with limited options and little time to act.
We are proud of the work we are doing to advance treatments for ES-SCLC. Along with our partner, Roche, we are presenting data at ASCO 2025, for a combination treatment in the first-line maintenance setting. These results signal a potential paradigm shift in how ES-SCLC patients are treated.
Our work in ES-SCLC exemplifies how Jazz’s focus on high unmet need cancers can translate into meaningful clinical progress.
But clinical data is just one part of the equation. We are equally focused on addressing the barriers people face outside the trial setting, including barriers to access, participation, and feeling supported through their treatment journey. For example, a new video series on the Nothing Small About It website features thoracic and geriatric oncologist Dr. Carolyn Presley discussing the importance of wellbeing and sharing guidance around different aspects of wellness, including financial health, mental health, and physical health, to help patients navigate the complexities of SCLC.
That’s why our pipeline strategy continues to evolve, not only scientifically, but in how we think about delivering real-world impact. We aim to pursue science that improves outcomes, while enabling patients and their care teams to navigate cancer with more clarity and support.
As we look to the future, we remain committed to expanding our oncology portfolio, deepening our scientific capabilities, and helping shape a more personalized model of care. We’re proud to stand alongside the oncology community in our shared pursuit of better outcomes for patients and their families worldwide.
Read more about how our evolving science is changing the outlook for small cell lung cancer.
iRodriguez E, Lilenbaum RC. Small cell lung cancer: past, present, and future. Curr Oncol Rep. 2010 Sep;12(5):327-34. doi: 10.1007/s11912-010-0120-5. PMID: 20632219.
